Inappropriate Hedgehog (Hh) signaling has been directly linked to medulloblastoma (MB), a common malignant brain tumor in children. GDC-0449 is an Hh pathway inhibitor (HPI) currently under clinical investigation as an anti-cancer agent.
Introduction
MB is a primitive neuroectodermal tumor of the cerebellum, which is thought to originate from immature granule neural precursors (GNPs) located in the external granule layer (1) . It is the most common brain malignancy among children 0-4 years old and accounts for nearly 18% of pediatric intracranial tumors, with 350 new cases being diagnosed each year in the US (2) . Many patients still succumb to this disease and a large number of survivors suffer from debilitating therapy-related side effects, highlighting the need for alternative therapies.
Hh signaling is indispensable for normal embryonic development, yet this pathway is mostly dormant in healthy adults (see ref. (3) for a comprehensive review). GDC-0449 is an orally bioavailable SMO antagonist that has produced promising anti-tumor responses in a Phase I study of patients with advanced basal cell carcinoma (BCC), a type of skin cancer also driven by mutations in Hh pathway components (7) .
Furthermore, GDC-0449 promptly regressed tumors and reduced symptoms in a 26-yearold man with metastatic MB that was unmanageable by conventional therapies (8) .
However, the dramatic response of this patient to GDC-0449 treatment was transient, as instrument (Stratagene) using 25 ng of genomic DNA/reaction. Target loci were compared to murine SINE1 elements and quantified on standard curves of normal diploid mouse DNA as described (12) using the following primers:
Results

D473
is important for SMO inhibition by GDC-0449. We previously reported that mutation of a conserved aspartic acid residue in SMO interferes with GDC-0449 binding and its ability to suppress tumor growth, without dramatically altering the signaling activity of this protein (9) . To better characterize the role of D473 in SMO function, we substituted this residue with every amino acid and analyzed the resulting mutants in a Gli-luciferase reporter assay in the presence or absence of 1 μM GDC-0449
( Fig. 1A ; Supplementary Fig. S1A ). Apart from the possibly misfolded SMO-D473P, all mutants induced Hh pathway activity and were less sensitive to GDC-0449 inhibition than SMO-WT. The seemingly responsive D473V mutant was partially drug-resistant in a dose response assay ( Supplementary Fig. S1B) . Surprisingly, the conservative SMO-D473E mutant was also resistant to GDC-0449, despite maintaining a negative charge at this position. We confirmed cell surface expression for several of these mutants (Supplementary Fig. S1C and D) and tested their ability to bind GDC-0449 (Fig. 1B) .
Similar to SMO-D473H (9), resistance to this HPI correlated with a lack of SMObinding, indicating that D473 is critical for SMO inhibition by GDC-0449.
D473 could either be directly involved in GDC-0449 binding or could simply be required to maintain the correct SMO conformation for binding. Several mutants, including those with a positive charge such as D473K and D473R, were more active than SMO-WT and almost as active as the oncogenic SMO-M2 mutant ( Fig. 1A; 13 ), implying that D473 could be a structurally important residue. Consistent with this notion, SMO-D473K and SMO-D473R have auto-activating properties and, like SMO-M2, are resistant to inhibition by PTCH1 (Fig. 1C ).
E518 is also important for SMO inhibition by GDC-0449.
We used an alanine scan mutagenesis approach to identify additional residues in SMO critical for GDC-0449 binding ( Fig. 2A) . Assuming that GDC-0449 binds SMO in a manner reminiscent of GPCRs binding to their ligands, we mutated regions known to be important for such interactions (14) . These include transmembrane helices (TM) 3, TM5, TM6 and TM7 and adjacent amino acids as well as the entire third extracellular loop of SMO, since it contains D473. We analyzed a total of 102 SMO mutants, using GDC-0449 binding as a Table S1 ). Most of the 21 new SMO mutants found to be deficient in GDC-0449 binding were either inactive with respect to signaling or not expressed at the cell surface. However, SMO-E518A showed significant signaling activity despite the presence of 1 μM GDC-0449 and proved to be partially resistant (Fig.   2B ). It appears that our binding assay is sensitive to even small changes in drug affinity for SMO, since certain mutants deficient in GDC-0449 binding could still be inhibited at high drug concentrations. We then introduced a more drastic amino acid substitution that reverses the charge at this position and which can be achieved through a single nucleotide change. This SMO-E518K mutant has activity comparable to SMO-WT (Supplementary Table S1 ), yet is completely resistant to GDC-0449 up to 1 μM (Fig. 2B ). Thus, we have identified E518 as a prospective novel mutation site in SMO that could confer resistance to GDC-0449.
A screen of chemically diverse HPIs identified several SMO-D473H and SMO-E518K antagonists. To identify SMO mutant inhibitors as potential therapeutics for
GDC-0449-resistant tumors, we screened a panel of 53 antagonists (representative compounds are shown in Fig. 3A ) with potent activity against the wild type protein (Fig.   3B ). These inhibitors were either identified in high-throughput screens (both in house and by others) or were generated by hit-to-lead optimization of screening hits using traditional medicinal chemistry methods. The two GDC-0449-resistant mutants displayed clearly different requirements for inhibition in our Gli-luciferase reporter assay, as SMO-E518K was completely resistant to the natural plant alkaloid cyclopamine yet sensitive to the hyrazinoimine SANT-1 (15), while SMO-D473H was partially resistant to both compounds. In addition, various C-ring amide analogs of GDC-0449 had robust potency against SMO-E518K, but were weakly active against SMO-D473H, as exemplified by compound 1 (see Fig. 3A for A-, B-, and C-ring nomenclature). However, the benzimidazole HhAntag (16) was essentially equipotent against all SMO alleles, while quinoxalines (represented by compound 2) were found to have low activity against both mutants. Compound 3 showed measurable activity against SMO-D473H despite having an identical C-ring to GDC-0449, and this general class of bis-amides showed improved potencies against both mutants once the optimal substitution pattern was found, exemplified by compound 4. 
Compound 5 inhibits tumor growth mediated by GDC-0449-resistant SMO.
To determine whether compound 5 could inhibit drug resistant SMO in vivo, we generated mice with subcutaneous allografts of the murine Ptch GDC-0449 and compound 5 both interfere with SMO translocation to the primary cilium. Recently, several groups reported that diverse antagonists differentially affect the trafficking and localization of SMO to the primary cilium (17) (18) (19) Figure S4) .
Although cyclin D1 and GLI2 act downstream of SMO and have previously been implicated in the development of MB, we formally cannot rule out involvement of the other genomic alterations in GDC-0449 resistance. The Ccnd1 and Gli2 amplifications were independently confirmed by qPCR in SG102 and SG152, when compared to GDC-0449-sensitive control and SMO mutant SG274 tumors (Fig. 5B ). These genomic alterations correlated with enhanced mRNA expression and elevated protein levels of both cyclin D1 and GLI2 (Fig. 5B-D) . GLI2 contains an amino-terminal repressor domain that when deleted results in a constitutively active protein with 30 times higher transcriptional activity (21) . Sequencing of Gli2 in model SG152 revealed no truncating mutations and both the full-length and repressor forms were detected by immunoblotting, indicating that GLI2 processing was relatively normal (Fig. 5C ). Finally, GDC-0449 down regulated cyclin D1 levels in control tumors, consistent with Ccnd1 being an Hh target gene (22), but did not in SG102 tumors (Fig. 5D ), despite decreasing Gli1 mRNA levels (Fig. 5A ).
HPI resistant MB allografts are sensitive to PI3K inhibition. Given the identification of resistance mechanisms downstream of SMO, we looked at other signaling pathways implicated in MB to see if targeting any of these might be an alternative therapeutic approach to combating GDC-0449 resistance. Abnormal phosphoinositide3-kinase (PI3K)/AKT signaling promotes tumor growth and survival of many human cancers, including MB (23, 24). We therefore examined the level of activated AKT (phosphorylated at Ser473) and activated S6 (phosphorylated at Ser235/236) in our MB allograft models and were able to detect both phospho-proteins, suggesting that the PI3K/AKT pathway is active in these tumors (Fig. 6A) . However, it is
Discussion
SMO is the first GPCR-like protein that has been targeted therapeutically for an oncology indication. As for many other cancer therapies (29) , resistance via mutation of the drug target has quickly emerged (9) . To better characterize the role of D473 in HPI resistance we replaced this residue with every amino acid and found that, while all functional mutants were GDC-0449-resistant to varying degrees, certain substitutions led to increased signaling, potentially via induction of a conformational change in SMO.
Although D473H displayed no significant increase in signaling in our in vitro reporter assay, these observations suggest that modification at this site could result in a growth advantage for mutants that may contribute to their emergence prior to drug treatment.
Thus mutation of D473 may confer a selective growth advantage in vivo.
Using alanine scan mutagenesis of candidate ligand-binding regions, we identified In addition to identifying several potent SMO mutant inhibitors, our screen of chemically diverse HPIs provided some unexpected insights into the binding mode of GDC-0449. Substituting the A-ring of GDC-0449 with one that contains both a hydrogen bond donor and acceptor (as in compound 3) improved potency against SMO-D473H, while SMO-E518K was more sensitive to changes in the C-ring (like those introduced by compound 1). It is therefore tempting to speculate that D473 and E518 are part of a GDC-0449 binding site in SMO and interact with the A-and C-ring, respectively. These residues are likely shared with or in close proximity to other binding sites, as several SMO antagonists were less effective against these GDC-0449-resistant mutants. Cocrystallization of SMO with GDC-0449 may be required to elucidate the binding site and precise contribution of these residues. HhAntag twice daily (n=6, red squares).
Tumor volume traces of individual mice are shown in Supplementary Fig. S2 . 
